Skip to content

US · TAK · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Takeda Pharmaceutical Company Limited (TAK) intrinsic value and stock valuation

$21.77as of 2026-11-21 · Mkt cap 53.21B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Takeda Pharmaceutical Company Limited DCF and intrinsic value

InvestorsCraft values TAK with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from TAK’s statements →

Takeda Pharmaceutical Company Limited Graham Number

Graham Number: $1,897.34d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Tokyo, OS 103-8668 takeda.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$4.78T+8.4% 5y CAGRd
20122026
Net income
$203.3B-11.6% 5y CAGRd
20122026
Free cash flow
$626.8B-4.1% 5y CAGRd
20122026
Total equity
$7.81T+8.6% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$4.78T$4.58T$4.26T$4.03T$3.57T
Operating income$573B$342.6B$214.1B$490.5B$460.8B
Net income$203.3B$107.9B$144.1B$317B$230.1B
EPSd$63.4M$33.6M$45.6M$101M$72.9M
Operating cash flow$1.04T$1.06T$716.3B$977.2B$1.12T
Capital expenditure-$-414.66B-$-379.63B-$-480.73B-$-633.69B-$-186.04B
Free cash flow$626.8B$677.6B$235.6B$343.5B$937.1B
Total assets$15.5T$14.2T$15.1T$14T$13.2T
Total debt$4.9T$4.52T$4.84T$4.38T$4.35T
Net debt$4.31T$4.13T$4.39T$3.85T$3.5T
Total equity$7.81T$6.94T$7.27T$6.35T$5.68T
Cash and short-term investments$597.6B$405.6B$472.9B$553.7B$875B
Income statement
20262025202420232022
Revenue$4.78T$4.58T$4.26T$4.03T$3.57T
Cost of revenue$2.34T$1.58T$1.43T$1.24T$1.11T
Gross profit$2.44T$3T$2.83T$2.78T$2.46T
Research and development expenses$716.7B$730.2B$729.9B$633.3B$526.1B
Selling, general and administrative expenses$1.15T$1.1T$1.05T$997.3B$886.4B
Other expenses$0.00$823.8B$834.4B$662.3B$588.9B
Operating expenses$1.87T$2.66T$2.62T$2.29T$2T
Cost and expenses$4.2T$4.24T$4.05T$3.54T$3.11T
Interest income$223.9B$19.6B$78.1M$5.51B$4.59B
Interest expense$379.1B$137.3B$1.06B$117B$122.4B
Depreciation and amortization$764.6B$761.4B$644.5B$664.4B$583.2B
Ebitda$1.42T$1.21T$1.14T$1.28T$1.18T
Operating income$573B$342.6B$214.1B$490.5B$460.8B
Total other income/expenses, net-$-297.16B-$-167.5B-$-161.28B-$-115.42B-$-158.27B
Income before tax$275.9B$175.1B$52.8B$375.1B$302.6B
Income tax expense$72.3B$66.9B-$-91.41B$58.1B$72.4B
Net income$203.3B$107.9B$144.1B$317B$230.1B
Weighted average shares outstanding$3.15B$3.21B$3.13B$3.1B$3.13B
Weighted average diluted shares outstanding$3.21B$3.21B$3.16B$3.14B$3.15B
Balance sheet
20262025202420232022
Cash and short-term investments$597.6B$405.6B$472.9B$553.7B$875B
Net receivables$880.1B$725.3B$697.6B$681.7B$724.4B
Inventory$1.4T$1.22T$1.21T$986.5B$853.2B
Total current assets$3.1T$2.52T$2.56T$2.4T$2.59T
Property, plant and equipment, net$2.13T$1.97T$1.99T$1.69T$1.58T
Goodwill and intangible assets$9.27T$8.96T$9.68T$9.06T$8.23T
Long-term investments$450.7B$361.9B$430.6B$378.9B$330.1B
Total non-current assets$12.4T$11.7T$12.6T$11.6T$10.6T
Total assets$15.5T$14.2T$15.1T$14T$13.2T
Accounts payable$493.5B$308.5B$320B$307.5B$295.9B
Short-term debt$514.4B$548.9B$367.3B$339.6B$204B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.44T$2.51T$2.31T$2.48T$2.15T
Long-term debt$4.39T$3.97T$4.48T$4.04T$4.14T
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.27T$4.81T$5.52T$5.12T$5.35T
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$7.71T$7.31T$7.83T$7.6T$7.49T
Common stock$1.7T$1.69T$1.68T$1.68T$1.68T
Retained earnings$1.06T$1.19T$1.39T$1.54T$1.48T
Accumulated other comprehensive income (loss)$3.31T$2.35T$2.51T$1.51T$934.2B
Total equity$7.81T$6.94T$7.27T$6.35T$5.68T
Total investments$450.7B$382.4B$445.7B$399B$355.4B
Total debt$4.9T$4.52T$4.84T$4.38T$4.35T
Net debt$4.31T$4.13T$4.39T$3.85T$3.5T
Cash flow statement
20262025202420232022
Net income-$-152.13B$108.1B$144.2B$317B$230.2B
Depreciation and amortization$721.1B$761.4B$728B$664.4B$583.2B
Stock-based compensation$72.8B$72.9B$70.9B$60.7B$43.4B
Change in working capital$199.9B-$-59.37B-$-256B-$-25.26B$98.6B
Accounts receivable-$-70.17B-$-58.96B$15.1B$75.1B$127.3B
Inventory-$-61.29B-$-34.97B-$-115.74B-$-79.16B-$-46.15B
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$1.04T$1.06T$716.3B$977.2B$1.12T
Investments in property, plant and equipment-$-176B-$-200.8B-$-175.42B-$-140.66B-$-123.25B
Acquisitions, net$33.6B$77.2B$20B$7.96B-$-21.48B
Net cash used for investing activities-$-369.14B-$-367.06B-$-463.86B-$-607.1B-$-198.13B
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-51.6B-$-51.86B-$-2.33B-$-26.93B-$-77.53B
Dividends paid-$-311.9B-$-302.5B-$-287.19B-$-279.42B-$-283.67B
Net cash used for financing activities-$-496.82B-$-751.43B-$-354.42B-$-709.15B-$-1.07T
Net change in cash$209.9B-$-72.69B-$-75.73B-$-316.17B-$-116.53B
Cash at end of period$595.1B$385.1B$457.8B$533.5B$849.7B
Operating cash flow$1.04T$1.06T$716.3B$977.2B$1.12T
Capital expenditure-$-414.66B-$-379.63B-$-480.73B-$-633.69B-$-186.04B
Free cash flow$626.8B$677.6B$235.6B$343.5B$937.1B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Takeda Pharmaceutical Company Limited

        Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.

        CEO
        Julie So-Young Kim
        Employees
        47.03K
        Beta
        0.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Takeda Pharmaceutical Company Limited (TAK)?

        Takeda Pharmaceutical Company Limited (TAK) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TAK undervalued?

        TAK trades at a price of $21.77 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.